Repligen Co. (NASDAQ:RGEN) Shares Acquired by V Square Quantitative Management LLC

V Square Quantitative Management LLC grew its position in Repligen Co. (NASDAQ:RGEN) by 76.8% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 564 shares of the biotechnology company’s stock after acquiring an additional 245 shares during the period. V Square Quantitative Management LLC’s holdings in Repligen were worth $101,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of RGEN. Benjamin F. Edwards & Company Inc. raised its position in shares of Repligen by 152.1% during the 4th quarter. Benjamin F. Edwards & Company Inc. now owns 242 shares of the biotechnology company’s stock worth $43,000 after purchasing an additional 146 shares during the last quarter. Principal Securities Inc. acquired a new position in shares of Repligen during the 4th quarter worth about $48,000. Signaturefd LLC raised its position in shares of Repligen by 48.4% during the 4th quarter. Signaturefd LLC now owns 417 shares of the biotechnology company’s stock worth $75,000 after purchasing an additional 136 shares during the last quarter. Picton Mahoney Asset Management acquired a new position in shares of Repligen during the 4th quarter worth about $90,000. Finally, Operose Advisors LLC acquired a new position in shares of Repligen during the 3rd quarter worth about $99,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

Repligen Stock Down 1.0 %

Shares of NASDAQ RGEN opened at $124.35 on Tuesday. The company has a 50-day moving average of $159.58 and a 200 day moving average of $176.32. Repligen Co. has a 12-month low of $110.45 and a 12-month high of $211.13. The company has a current ratio of 6.35, a quick ratio of 5.24 and a debt-to-equity ratio of 0.26. The stock has a market cap of $6.95 billion, a PE ratio of 497.42, a P/E/G ratio of 4.19 and a beta of 1.04.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings results on Wednesday, May 1st. The biotechnology company reported $0.28 earnings per share for the quarter, missing the consensus estimate of $0.29 by ($0.01). Repligen had a net margin of 2.44% and a return on equity of 3.95%. The firm had revenue of $151.31 million during the quarter, compared to analysts’ expectations of $150.06 million. During the same period last year, the company earned $0.64 EPS. The business’s quarterly revenue was down 17.1% on a year-over-year basis. As a group, sell-side analysts predict that Repligen Co. will post 1.46 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts recently weighed in on the stock. JPMorgan Chase & Co. reduced their price target on shares of Repligen from $230.00 to $200.00 and set an “overweight” rating for the company in a research report on Thursday, May 2nd. Stifel Nicolaus upped their price objective on shares of Repligen from $165.00 to $207.00 and gave the company a “buy” rating in a research note on Thursday, February 22nd. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $197.75.

Insider Activity

In other news, Director Martin D. Madaus purchased 1,615 shares of the company’s stock in a transaction dated Friday, June 14th. The stock was acquired at an average price of $124.94 per share, with a total value of $201,778.10. Following the purchase, the director now directly owns 4,613 shares in the company, valued at approximately $576,348.22. The acquisition was disclosed in a document filed with the SEC, which is available at this link. In related news, Director Martin D. Madaus acquired 1,615 shares of the stock in a transaction that occurred on Friday, June 14th. The stock was purchased at an average price of $124.94 per share, with a total value of $201,778.10. Following the transaction, the director now owns 4,613 shares of the company’s stock, valued at approximately $576,348.22. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Anthony Hunt acquired 2,000 shares of the stock in a transaction that occurred on Friday, June 14th. The shares were bought at an average cost of $124.08 per share, with a total value of $248,160.00. Following the transaction, the chief executive officer now directly owns 165,177 shares in the company, valued at approximately $20,495,162.16. The disclosure for this purchase can be found here. Corporate insiders own 1.20% of the company’s stock.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.